Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens

Clinical and Experimental Immunology

Volumn 113, Issue 1, 1998, Pages 85-91

  Kelleher, A D ^a,c   Roggensack, M ^a   Emery, S ^a   Carr, A ^a   French, M A ^b   Cooper, D A ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

HIV; IL 2; Proliferative responses; Therapy

Indexed keywords

ANTIRETROVIRUS AGENT; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; LAMIVUDINE; MACROGOL; MITOGENIC AGENT; NUCLEOSIDE ANALOG; OKT 3; PHYTOHEMAGGLUTININ; RECOMBINANT INTERLEUKIN 2; STREPTODORNASE PLUS STREPTOKINASE; TETANUS TOXOID;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VIRUS LOAD;

ADULT; CD4 LYMPHOCYTE COUNT; CELL DIVISION; HIV ANTIGENS; HIV INFECTIONS; HUMANS; IMMUNOLOGIC MEMORY; INFUSIONS, INTRAVENOUS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MITOGENS; PILOT PROJECTS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; TETANUS TOXOID; VIRAL LOAD;

EID: 0031869582     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1998.00633.x     Document Type: Article

References (26)

1. Schrier R, Gnann JJ, Landes R et al. T cell recognition of HIV synthetic peptides in a natural infection. J Immunol 1989; 142:1166-76.
2. Wahren B, Rosen J, Sandstrom E, Mathiesen T, Modrow S, Wigzell H. HIV-1 peptides induce a proliferative response in lymphocytes from infected persons. J Acq Imm Def Syndr 1989; 4:448-56.
3. Bell SJD, Cooper DA, Kemp BE, Doherty RR, Penny R. Heterogeneous effects of IL-2 on HIV-specific cell-mediated immunity (CMI). Clin Exp Immunol 1992; 90:6-12.
4. Krowka J, Stites D, Mills J, Hollander H, McHugh T, Busch M, Wilhelm L, Blackwood L. Effects of interleukin 2 and large envelope glycoprotein (gp120) of human immunodeficiency virus (HIV) on lymphocyte proliferative responses to cytomegalovirus. Clin Exp Immunol 1988; 72:179-85.
5. Seder RA, Grabstein KH, Berzofsky JA, McDyer JF. Cytokine interactions in human immunodeficiency virus-infected individuals: roles of interleukin (IL)-2, IL-12, and IL-15. J Exp Med 1995; 182:1067-78.
6. Rook AH, Masur H, Lane HC et al. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with acquired immunodeficiency syndrome. J Clin Invest 1983; 72:398-404.
7. Barker E, Mackewicz CE, Levy JA. Effects of TH1 and TH2 cytokines on CD8+ cell response against human immunodeficiency virus: implications for long term survival. Proc Natl Acad Sci USA 1995; 92:11135-9.
8. Adachi Y, Oyaizu N, Than S, McCloskey W, Pahwa S. IL-2 rescues in vitro lymphocyte apoptosis in patients with HIV infection, correlation with its ability to block culture-induced down-modulation of Bcl-2. J Immunol 1996; 157:4184-93.
9. Kovacs JA, Vogel S, Albert JM et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996; 335:1350-6.
10. Kovacs JA, Baseler M, Dewar RJ et al. Increases in CD4 lymphocytes with intermittent courses of interleukin-2 in patients with Human Immunodeficiency Virus infection, a preliminary study. N Engl J Med 1995; 332:567-75.
11. De Paoli P, Zanussi S, Simonelli C et al. Effects of subcutaneous interleukin-2 on CD4 subsets and in vitro cytokine production in HIV+ subjects. J Clin Invest 1997; 100:2737-43.
12. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996; 173:321-9.
13. Bell SJD, Cooper DA, Kemp BE et al. Definition of an immunodominant T cell epitope contained in envelope gp41 sequence of HIV-1. Clin Exp Immunol 1992; 87:37-45.
14. Mills KHG, Kitchin PA, Mahon BP, Barnard AL, Adams SE, Kingsman SM, Kingsman AJ. HIV p24-specific helper T-cell clones from immunised primates recognize highly conserved regions of HIV-1. J Immunol 1990; 144:1677-83.
15. Vyakarnam A, Matear P, Craneburg C, Michie C, Beverley PC, Wahren B, Gill SK, Weller I. T cell response to peptides covering p24 region of HIV-1 occur in HIV-1 seronegative individuals. Int Immunol 1991; 3:939-47.
16. Cease KB, Margali H, Cornette JL et al. Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide. Proc Natl Acad Sci USA 1987; 84:4249-53.
17. Clerici M, Stocks NI, Zajac RA, Boswell RN, Bernstein DC, Mann DL, Shearer GM, Berszosky JA. Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals. Nature 1989; 339:383-5.
18. Berzofsky JA, Bensussan A, Cease KB et al. Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. Nature 1988; 334:706-8.
19. Ahlers JD, Pendleton CD, Dunlop N, Minassian A, Nara PL, Berszofsky JA. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide liked to a V3 loop peptide 18 inducing strong neutralising antibody responses in mice of multiple MHC haplotypes after two immunisations. J Immunol 1993; 150:5647-55.
20. Mutch D, Underwood J, Geysen M, Rodda S. Comprehensive T-cell epitope mapping of HIV-1 env antigens reveals many areas recognized by HIV-1-seropositive and by low-risk HIV-1-seronegative individuals. J Acquir Imm Def Syn 1994; 7:879-90.
21. Ballet J-J, Couderc L-J, Rabian-Herzog C, Duval-Roy C, Janier M, Danon F, Clauvel J-P, Seligmann M. Impaired T-lymphocyte-dependent immune responses to microbial antigens in patients with HIV-1 associated persistent generalised lymphadenopathy. AIDS 1988; 2:291-7.
22. Tassinari P, Deibis L, Bianca I, Bianca NE, de Perez GE. Decreased T-cell proliferative response to common environmental antigens could be an indicator of early human immunodeficiency virus-mediated lymphocyte lesions. Clin Diag Lab Immunol 1995; 2:404-7.
23. Stanley SK, Ostrowski MA, Justement JS et al. Effect of immunisation with common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996; 334:1222-30.
24. Teppler H, Kaplan G, Smith K, Cameron P, Montana A, Meyn P, Cohn Z. Efficacy of low doses of polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection. J Infect Dis 1993; 167:291-8.
25. Wood R, Montoya JG, Kundu SM, Schwartz DH, Merigan TC. Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type-1 infection: a phase 1/11 study. J Infect Dis 1993; 167:519-5.
26. Connors M, Kovacs JA, Krevat S et al. HIV infection induces changes in CD4 (+) T-cell phenotype and depletions within the CD4 (+) T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997; 3:533-40.